Disease-modifying therapies as positive predictors of quality of life for Sudanese patients with multiple sclerosis: a cross-sectional study DOI Creative Commons

Eman Saleh Omar,

Hayat M. Suliman, Bashier Osman

et al.

The Egyptian Journal of Neurology Psychiatry and Neurosurgery, Journal Year: 2024, Volume and Issue: 60(1)

Published: June 20, 2024

Abstract Background Multiple sclerosis (MS) is an immune-mediated, neurodegenerative disease with devastating, disabling, and negative impacts on the patients’ quality of life (QoL). Although MS was not known in Sudan, it seems to be rising recent years. This a cross-sectional, hospital-based study aimed at assessing impact medications QoL neurology clinics Khartoum City. Sixty-four patients diagnosed were recruited. SF-36 questionnaire used assess QoL. Data collected from records addition hand-delivered questionnaire. analyzed using ANOVA test logistic regression; p ≤ 0.05 considered statistically significant. Results The majority females north Sudan (92.2%). mean age 28.2 ± 6.5. Relapsing–remitting most type (65.6%). Fatigue urinary incontinence observed symptoms. All had vitamin D deficiency (5–20 ng/ml). Disease-modifying therapies (DMTs) prescribed 37.5% patients. overall 53.9 14.7 fair physical mental health (51.8 19.2 57.0 10.9, respectively). Patients DMTs showed significantly good compared azathioprine ( 0.01), corticosteroids 0.01.), no 001). Azathioprine (OR = 0.12; 0.05), 0.14; 0.05) treatment 0.01; 0.001) negatively affected when DMTs. Vitamin supplementation 0.01) associated Conclusions prominent young females’ descendants Sudanese northern tribes. improve devastating effect QoL,

Language: Английский

An update on the treatment and management of cognitive dysfunction in patients with multiple sclerosis DOI Creative Commons
Ermelinda De Meo, Emilio Portaccio, Raffaello Bonacchi

et al.

Expert Review of Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 13, 2025

Introduction Cognitive impairment (CI) occurs in 34-70% of multiple sclerosis (MS) patients, significantly impacting quality life. CI can occur independently physical disability, even those with 'benign MS.' deficits are heterogeneous, but common areas affected include processing speed, memory, and executive functions.

Language: Английский

Citations

1
Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis DOI
Gianmarco Abbadessa, Giuseppina Miele, Elisabetta Maida

et al.

Multiple Sclerosis Journal, Journal Year: 2023, Volume and Issue: 29(7), P. 779 - 788

Published: Jan. 22, 2023

Ocrelizumab is a humanized monoclonal antibody designed to bind the CD20 molecule, resulting in rapid depletion of B-cells; however, it has been shown that lymphocyte subpopulations other than B-cells are affected by drug. To review effects ocrelizumab on circulating lymphocytes and identify candidate biomarkers predict monitor treatment response. A literature search for most relevant articles from 2006 2022 was conducted PubMed Scopus. The effect peripheral immune system goes beyond also depletes T + lymphocytes. Further, reshapes T-cell response toward low inflammatory profile induces an increase CD8 regulatory cell percentage. higher Body Mass Index B-cell count at baseline have associated with early reappearance. Serum neurofilament light chain reduction exerts broad immunomodulatory may be tailored based patients’ clinical biological profiles.

Language: Английский

Citations

15
Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects DOI Creative Commons
Piotr Olejnik, Zuzanna Roszkowska, Sylwia Adamus

et al.

Pharmacological Reports, Journal Year: 2024, Volume and Issue: 76(5), P. 926 - 943

Published: Aug. 23, 2024

Abstract Multiple sclerosis (MS) is a chronic autoimmune disease characterized by pathological processes of demyelination, subsequent axonal loss, and neurodegeneration within the central nervous system. Despite availability numerous disease-modifying therapies that effectively manage this condition, there an emerging need to identify novel therapeutic targets, particularly for progressive forms MS. Based on contemporary insights into pathophysiology, ongoing efforts are directed toward developing innovative treatment modalities. Primarily, monoclonal antibodies have been extensively investigated their efficacy in influencing specific pathways not yet targeted. Emerging approaches emphasizing cellular mechanisms, such as chimeric antigen receptor T cell therapy targeting immunological cells, attracting increasing interest. The evolving understanding microglia involvement ferroptotic mechanisms MS pathogenesis presents further avenues targeted therapies. Moreover, strategies extend beyond conventional encompass interventions target alterations microbiota composition dietary modifications. These adjunctive hold promise complementary methods holistic management This narrative review aims summarize current outline potential individuals with

Language: Английский

Citations

3
Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab DOI Creative Commons
Lisa Beckers,

P. Baeten,

Veronica Popescu

et al.

Clinical Immunology, Journal Year: 2024, Volume and Issue: 259, P. 109894 - 109894

Published: Jan. 5, 2024

B cell depletion by the anti-CD20 antibody ocrelizumab is effective in relapsing-remitting (RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological changes peripheral blood of a real-world MS cohort after 6 12 months ocrelizumab. All RRMS most PPMS patients (15/20) showed treatment response. Ocrelizumab not only reduced CD20

Language: Английский

Citations

1
Impact of Mast Cell Activation on Neurodegeneration: A Potential Role for Gut–Brain Axis and Helicobacter pylori Infection DOI Creative Commons
Marina Boziki, Paschalis Theotokis, Evangelia Kesidou

et al.

Neurology International, Journal Year: 2024, Volume and Issue: 16(6), P. 1750 - 1778

Published: Dec. 6, 2024

Background: The innate immune response aims to prevent pathogens from entering the organism and/or facilitate pathogen clearance. Innate cells, such as macrophages, mast cells (MCs), natural killer and neutrophils, bear pattern recognition receptors are thus able recognize common molecular patterns, pathogen-associated patterns (PAMPs), damage-associated (DAMPs), later occurring in context of neuroinflammation. An inflammatory component pathology otherwise “primary cerebrovascular neurodegenerative” disease has recently been recognized targeted a means therapeutic intervention. Activated MCs multifunctional effector generated hematopoietic stem that, together with dendritic represent first-line defense mechanisms against tissue destruction. Methods: This review summarize evidence MC implication pathogenesis neurodegenerative diseases, namely, Alzheimer’s disease, Parkinson’s amyotrophic lateral sclerosis, Huntington’s multiple sclerosis. Results: In view recent that gut–brain axis may be implicated diseases characterization neuroinflammatory these this also focuses on potential mediators bi-directional communication possible role Helicobacter pylori, gastric known alter homeostasis towards local systemic pro-inflammatory responses. Conclusion: As pylori infection offer targets intervention implications for more clinical translational is needed elucidate field.

Language: Английский

Citations

1
The NLRP3 inflammasome: A central player in multiple sclerosis DOI
Almudena Otálora-Alcaraz, Thomas Reilly,

Martí Oró-Nolla

et al.

Biochemical Pharmacology, Journal Year: 2024, Volume and Issue: unknown, P. 116667 - 116667

Published: Dec. 1, 2024

Language: Английский

Citations

1
Current advances in the pharmacological prevention and management of cognitive dysfunction in multiple sclerosis DOI
Angelo Bellinvia, Emilio Portaccio, Maria Pia Amato

et al.

Expert Opinion on Pharmacotherapy, Journal Year: 2022, Volume and Issue: 24(4), P. 435 - 451

Published: Dec. 21, 2022

Introduction Cognitive impairment (CI) is a core feature of Multiple Sclerosis (MS), being detectable in up to 65% subjects. Treatment CI can be considered paramount importance. However, no standardized strategies are available date define the best treatment approach, especially for pharmacological management.Areas covered In this narrative review, authors outline latest advances management MS, including Disease Modifying Treatments (DMTs) which indirectly may or not influence and symptomatic drugs. Selected publications were restricted those written English, reporting on an adult relapsing-remitting MS progressive sample, assessing effects (at least) 1 DMT longitudinal design, data one cognitive test performed at baseline follow-up, published between January 2018 May 2022.Expert opinion Recent encouraging inspiring future studies. Overall, there preliminary evidence beneficial effect DMTs cognition, particularly high-efficacy DMTs. As treatments, dalfampridine appears only medication with robust positive cognition. definition clinically meaningful change/improvement functions remains unmet need. Future studies should assess role other patient-related factors that associated better response treatments investigate possible multimodal interventions

Language: Английский

Citations

4
Symbol Digit Modalities Test in progressive multiple sclerosis DOI Open Access
Bartosz Gajewski, Iwona Karlińska, Mariusz Stasiołek

et al.

Neurologia i Neurochirurgia Polska, Journal Year: 2024, Volume and Issue: 58(3), P. 221 - 232

Published: March 21, 2024

Language: Английский

Citations

0
How does Nogo-A signalling influence mitochondrial function during multiple sclerosis pathogenesis? DOI Creative Commons

Danica Nheu,

Steven Petratos

Neuroscience & Biobehavioral Reviews, Journal Year: 2024, Volume and Issue: 163, P. 105767 - 105767

Published: June 15, 2024

Multiple sclerosis (MS) is a severe neurological disorder that involves inflammation in the brain, spinal cord and optic nerve with key disabling neuropathological outcomes being axonal damage demyelination. When degeneration of axo-glial union occurs, consequence inflammatory to central nervous system (CNS) myelin, dystrophy death can lead large membranous structures from dead oligodendrocytes degenerative myelin deposited extracellular milieu. For first time, this review covers mitochondrial mechanisms maybe operative during MS-related neurodegenerative changes directly activated accumulating deposits associated inhibitory factors (MAIFs), include potent inhibitor neurite outgrowth, Nogo-A. Axonal may occur when Nogo-A binds signals through its cognate receptor, NgR1, multimeric complex, initially stall transport limit delivery important growth-dependent cargo subcellular organelles such as mitochondria for metabolic efficiency at sites disintegration inflammation. Metabolic axons fails active demyelination progressive neurodegeneration, preceded by stalled functional fuel integrity.

Language: Английский

Citations

0
Disease-modifying therapies as positive predictors of quality of life for Sudanese patients with multiple sclerosis: a cross-sectional study DOI Creative Commons

Eman Saleh Omar,

Hayat M. Suliman, Bashier Osman

et al.

The Egyptian Journal of Neurology Psychiatry and Neurosurgery, Journal Year: 2024, Volume and Issue: 60(1)

Published: June 20, 2024

Abstract Background Multiple sclerosis (MS) is an immune-mediated, neurodegenerative disease with devastating, disabling, and negative impacts on the patients’ quality of life (QoL). Although MS was not known in Sudan, it seems to be rising recent years. This a cross-sectional, hospital-based study aimed at assessing impact medications QoL neurology clinics Khartoum City. Sixty-four patients diagnosed were recruited. SF-36 questionnaire used assess QoL. Data collected from records addition hand-delivered questionnaire. analyzed using ANOVA test logistic regression; p ≤ 0.05 considered statistically significant. Results The majority females north Sudan (92.2%). mean age 28.2 ± 6.5. Relapsing–remitting most type (65.6%). Fatigue urinary incontinence observed symptoms. All had vitamin D deficiency (5–20 ng/ml). Disease-modifying therapies (DMTs) prescribed 37.5% patients. overall 53.9 14.7 fair physical mental health (51.8 19.2 57.0 10.9, respectively). Patients DMTs showed significantly good compared azathioprine ( 0.01), corticosteroids 0.01.), no 001). Azathioprine (OR = 0.12; 0.05), 0.14; 0.05) treatment 0.01; 0.001) negatively affected when DMTs. Vitamin supplementation 0.01) associated Conclusions prominent young females’ descendants Sudanese northern tribes. improve devastating effect QoL,

Language: Английский

Citations

0